- Home
- NUAIW vs SHPH Comparison
NUAIW vs SHPH Comparison
Compare NUAIW & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUAIW
- SHPH
- Stock Information
- Founded
- NUAIW N/A
- SHPH 2012
- Country
- NUAIW United States
- SHPH United States
- Employees
- NUAIW N/A
- SHPH N/A
- Industry
- NUAIW
- SHPH Biotechnology: Pharmaceutical Preparations
- Sector
- NUAIW
- SHPH Health Care
- Exchange
- NUAIW Nasdaq
- SHPH Nasdaq
- Market Cap
- NUAIW 2.1M
- SHPH 2.3M
- IPO Year
- NUAIW N/A
- SHPH 2022
- Fundamental
- Price
- NUAIW $0.08
- SHPH $3.38
- Analyst Decision
- NUAIW
- SHPH
- Analyst Count
- NUAIW 0
- SHPH 0
- Target Price
- NUAIW N/A
- SHPH N/A
- AVG Volume (30 Days)
- NUAIW N/A
- SHPH 35.9K
- Earning Date
- NUAIW N/A
- SHPH 08-13-2025
- Dividend Yield
- NUAIW N/A
- SHPH N/A
- EPS Growth
- NUAIW N/A
- SHPH N/A
- EPS
- NUAIW N/A
- SHPH N/A
- Revenue
- NUAIW N/A
- SHPH N/A
- Revenue This Year
- NUAIW N/A
- SHPH N/A
- Revenue Next Year
- NUAIW N/A
- SHPH N/A
- P/E Ratio
- NUAIW N/A
- SHPH N/A
- Revenue Growth
- NUAIW N/A
- SHPH N/A
- 52 Week Low
- NUAIW N/A
- SHPH $3.00
- 52 Week High
- NUAIW N/A
- SHPH $82.50
- Technical
- Relative Strength Index (RSI)
- NUAIW N/A
- SHPH 42.94
- Support Level
- NUAIW N/A
- SHPH $3.09
- Resistance Level
- NUAIW N/A
- SHPH $3.49
- Average True Range (ATR)
- NUAIW 0.00
- SHPH 0.21
- MACD
- NUAIW 0.00
- SHPH 0.00
- Stochastic Oscillator
- NUAIW 0.00
- SHPH 39.19
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.